79 related articles for article (PubMed ID: 11437313)
1. Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus.
Djavani M; Yin C; Lukashevich IS; Rodas J; Rai SK; Salvato MS
J Hum Virol; 2001; 4(2):103-8. PubMed ID: 11437313
[TBL] [Abstract][Full Text] [Related]
2. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
3. Replication-incompetent rabies virus vector harboring glycoprotein gene of lymphocytic choriomeningitis virus (LCMV) protects mice from LCMV challenge.
Takayama-Ito M; Lim CK; Yamaguchi Y; Posadas-Herrera G; Kato H; Iizuka I; Islam MT; Morimoto K; Saijo M
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006398. PubMed ID: 29659579
[TBL] [Abstract][Full Text] [Related]
4. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
[TBL] [Abstract][Full Text] [Related]
5. HLA-A2-restricted protection against lethal lymphocytic choriomeningitis.
Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Ting JP; Bui HH; Sette A; Buchmeier MJ
J Virol; 2007 Mar; 81(5):2307-17. PubMed ID: 17166907
[TBL] [Abstract][Full Text] [Related]
6. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.
Flatz L; Hegazy AN; Bergthaler A; Verschoor A; Claus C; Fernandez M; Gattinoni L; Johnson S; Kreppel F; Kochanek S; Broek Mv; Radbruch A; Lévy F; Lambert PH; Siegrist CA; Restifo NP; Löhning M; Ochsenbein AF; Nabel GJ; Pinschewer DD
Nat Med; 2010 Mar; 16(3):339-45. PubMed ID: 20139992
[TBL] [Abstract][Full Text] [Related]
7. Development of a new vaccine for the prevention of Lassa fever.
Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
[TBL] [Abstract][Full Text] [Related]
8. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.
Lukashevich IS; Patterson J; Carrion R; Moshkoff D; Ticer A; Zapata J; Brasky K; Geiger R; Hubbard GB; Bryant J; Salvato MS
J Virol; 2005 Nov; 79(22):13934-42. PubMed ID: 16254329
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus.
Moon-Walker A; Zhang Z; Zyla DS; Buck TK; Li H; Diaz Avalos R; Schendel SL; Hastie KM; Crotty S; Saphire EO
Cell Chem Biol; 2023 Apr; 30(4):403-411.e4. PubMed ID: 36990092
[TBL] [Abstract][Full Text] [Related]
10. Multimodal vaccination targeting the receptor binding domains of
Winter K; Houle S; Dozois CM; Ward BJ
Microbiol Spectr; 2024 Feb; 12(2):e0310922. PubMed ID: 38189293
[TBL] [Abstract][Full Text] [Related]
11. An attenuated lymphocytic choriomeningitis virus vector enhances tumor control in mice partly via IFN-I.
Chung YR; Awakoaiye B; Dangi T; Irani N; Fourati S; Penaloza-MacMaster P
J Clin Invest; 2024 Jun; ():. PubMed ID: 38861331
[TBL] [Abstract][Full Text] [Related]
12. Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine.
Feng W; Xiang Y; Wu L; Chen Z; Li Q; Chen J; Guo Y; Xia D; Chen N; Zhang L; Zhu S; Zhao KN
J Clin Lab Anal; 2022 Jun; 36(6):e24479. PubMed ID: 35527696
[TBL] [Abstract][Full Text] [Related]
13. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.
Hallam HJ; Hallam S; Rodriguez SE; Barrett ADT; Beasley DWC; Chua A; Ksiazek TG; Milligan GN; Sathiyamoorthy V; Reece LM
NPJ Vaccines; 2018; 3():11. PubMed ID: 29581897
[TBL] [Abstract][Full Text] [Related]
14. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.
Olschläger S; Flatz L
PLoS Pathog; 2013; 9(4):e1003212. PubMed ID: 23592977
[TBL] [Abstract][Full Text] [Related]
15. Advanced vaccine candidates for Lassa fever.
Lukashevich IS
Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493
[TBL] [Abstract][Full Text] [Related]
16. A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.
Shedlock DJ; Talbott KT; Cress C; Ferraro B; Tuyishme S; Mallilankaraman K; Cisper NJ; Morrow MP; Wu SJ; Kawalekar OU; Khan AS; Sardesai NY; Muthumani K; Shen H; Weiner DB
Vaccine; 2011 Sep; 29(39):6755-62. PubMed ID: 21238574
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles.
Cosset FL; Marianneau P; Verney G; Gallais F; Tordo N; Pécheur EI; ter Meulen J; Deubel V; Bartosch B
J Virol; 2009 Apr; 83(7):3228-37. PubMed ID: 19153226
[TBL] [Abstract][Full Text] [Related]
18. Reverse genetics approaches to combat pathogenic arenaviruses.
de la Torre JC
Antiviral Res; 2008 Dec; 80(3):239-50. PubMed ID: 18782590
[TBL] [Abstract][Full Text] [Related]
19. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
Carrion R; Patterson JL; Johnson C; Gonzales M; Moreira CR; Ticer A; Brasky K; Hubbard GB; Moshkoff D; Zapata J; Salvato MS; Lukashevich IS
Vaccine; 2007 May; 25(20):4093-102. PubMed ID: 17360080
[TBL] [Abstract][Full Text] [Related]
20. Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus.
Giacalone MJ; Zapata JC; Berkley NL; Sabbadini RA; Chu YL; Salvato MS; McGuire KL
Vaccine; 2007 Mar; 25(12):2279-87. PubMed ID: 17258845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
